Drug development is a time and cost-consuming long process. Conventionally, this involves the use of two-dimensional (2D) cell culture and animal testing. However, these methods often fail to mimic normal human physiology and drug metabolism, and sometimes complications may occur later because they do not appear in preclinical studies. With recent development of organ-on-a-chip devices, these biomimetic systems try to recapitulate human physiology more than other methods, and promise to largely replace animal studies and reduce costs and complications. Because gut is an important route for drug administration and absorption, gut-on-a-chip platform was developed. To develop a high throughput system, a recent work reported on using a multiplication array of several chip devices, demonstrating the efficiency in studying drug effect on gut barrier function as compared to conventional methods. Huge data was generated, and thus new multidisciplinary approach is needed where data collection, communication and analysis platforms need to be developed. This will enable validation of organ-on-a-chip approach and lay basis for its establishment as efficient and cost-effective tool in drug development.
Introduction
Current methods for assessing toxicity rely on the use of 2D culture and on the use of animal experiments. It is a long and costly process to get single medicine to the market. With new EU regulation (REACH policy for Registration, Evaluation, and Authorization of Chemicals) requesting the testing for toxicity of ~30,000 chemicals, we will need about 2. 
Gut-on-a-chip
With the recent advances made in microfluidics 6 and their application in developing lab-ona-chip 7 which was then combined with cells to have "organ-on-a-chip" 8 devices, it is becoming evident that such devices can be used as an alternative to animal experiments and provide large volume of data and can possibly be more biomimetic that animal experiments themselves as they employ human-derived cells.
Because many drugs are absorbed through the gut, gut-on-a-chip devices developed in 2012-2013 9,10 that has also flora included 11 to create such a testing platform. The system is In addition to organ-on-a-chip models mimicking normal physiology, organon-a-chip models for pathological conditions such as inflammation 12 , thrombosis 13 , degeneration 14 , and cancer 15 can also be developed and used for drug development studies.
Multiplied organ-on-a-chip devices
In next important logical step, which also constitutes the second milestone, recently It is for the first time that such comprehensive method is used for assessing drug concentration and exposure time on the integrity of intestinal epithelial barrier. It is the largest ever reported organ-on-a-chip system that used more than 20,000 data-points. The study opens new avenues for efficient and reliable future drug testing and development.
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Data Analysis
While the current work multiplies the organ-on-a-chip units many times creating huge and unprecedented amount of data, it requires parallel development of appropriate data analysis and management system as well as modelling. New multidisciplinary approach is thus needed and should be based on developing at least the following layers: 1. Sensing technologies, to sense and measure the cell responses accurately; 2. Communication technology, to collect time series data from maybe tens of thousands of sensors effectively;
3. Big data analysis and mining using effective artificial intelligence and machine learning algorithms; 4. Biochemical analysis and modelling, for drug design, testing and evaluation;
And, 5. Pathological models for the assessment of changes and effect of drug(s) in pathological situation(s). There is a different optimisation and working procedures of each layer. However, cross-layer optimisation would be crucial to enhance the efficiency and the 6 speed of the whole process. Another possible important application of the system is the online medical drug design or fine-tuning. The testing phase will just give us a conclusion about the validity of the drug and its effectiveness as well as possible side effects on the short and long-terms. However, with appropriately large number of data-points with many related sensors involved and online data analysis (using for example advanced machine learning and intelligent automation), it could be possible to modify the drug (e.g., chemical structure, compound concentration, design process) online. Within the closed-loop intelligent operations of drug-modifications and their impacts on cells, we will be able to perform thousands of directed (optimised) trials within proper duration of time. Current technical systems in terms of reliable electronics, sensors accuracy, computing facilities, smart algorithms, and intelligent micro-automated systems can be integrated as the foundation of the next generation drug design and development.
Conclusions
Gut on chip was developed to assess drug testing and aid drug development. To achieve high throughput, multiplications array of these devices were recently developed and its efficiency in such process was demonstrated. Data generated is huge and needs development of proper management. Multidisciplinary approach is necessary to develop novel functional platforms for drug testing and development based in multiplied organ-onchips, data collection, communication and analysis. Costs will hence, be saved, efficient medicines developed and risks to patients tremendously reduced. (1).
